An analysis of DAPA-HF indicates the efficacy and safety profile of dapagliflozin was consistent regardless of patient sex, highlighting the potential of the SGLT2 inhibitor for heart failure patients.
The American Heart Association is highlighting the effect of adverse pregnancy outcomes on risk of cardiovascular disease later in life among women. Check out this interview with the chair of the writing committee for more perspective on the statement.
An analysis of data from 130 women suggests those with hypertensive disorders of pregnancy were at an increased risk of cardiovascular disease later in life, even if they had no baseline history of cardiovascular disease.
Using data from the Women's Health Initiative, a new analysis found increased intake of plant protein was linked to lower risk of all-cause mortality, as well as deaths related to cardiovascular disease and dementia, in postmenopausal women.
An analysis of data obtained from the CARDIA study offers insight into the subsequent cardiovascular risks associated with gestational diabetes and how glucose control after pregnancy impacts this apparent increase risk.